Document Classification

Section Type: RESULTS

Text: Rosiglitazone, when compared with placebo, improved insulin sensitivity (mean [+ / - SD] change, 1. 5 + / - 2. 1 mg of glucose/kg of lean body mass per minute vs. -0. 4 + / - 1. 6 mg/kg per minute ; P = 0. 02), increased adiponectin levels (mean [+ / - SD], 2. 2 + / - 2. 2 micro g/mL vs. 0. 1 + / - 1. 1 microg/mL ; P = 0. 006), and reduced free fatty acid levels (mean [+ / - SD], -0. 09 + / - 0. 1 mmol/L vs. 0. 01 + / - 0. 1 mmol/L ; P = 0. 02).